Epidemiological and Clinical Characteristics of 944 Cases of 2019 Novel Coronavirus Infection of Non-COVID-19 Exporting City, Zhejiang, China

Kuang, Yani; Zhang, Huangqi; Zhou, Ronghui; Lin, Shuangxiang; Lin, Minjie; Wang, Jian; Pang, Peipei; Ma, Ling; Ji, Wenbin

doi:10.2139/ssrn.3543604

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 43 studies including 10,676 COVID-19 patients (confirmed by laboratory real-time reverse transcription polymerase chain reaction [RT-PCR] testing) were included in the overall analysis. [20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35]37,38,41,42,45,47,[49][50][51][52][53][54][55]58,59,[62][63][64][65][66][67][68][69][70][71]73,76 The pooled prevalence of diarrhea symptoms across these studies was 7.7% (95% CI, 7.2%-8.2%). When analyzing by country (studies from China vs studies from other countries), the pooled prevalence of diarrhea in studies from countries other than China was much higher at 18.3% (95% CI, 16.6%-20.1%).…”

Section: What Are the Gastrointestinal Manifestations Of Covid-19?mentioning

confidence: 99%

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

et al. 2020

View full text Add to dashboard Cite

BACKGROUND & AIMS: Multiple gastrointestinal (GI) symptoms, including diarrhea, nausea/vomiting, and abdominal pain, as well as liver enzyme abnormalities, have been variably reported in patients with coronavirus disease 2019 (COVID-19). This document provides best practice statements and recommendations for consultative management based on a systematic review and meta-analysis of international data on GI and liver manifestations of COVID-19. METHODS: We performed a systematic literature search to identify published and unpublished studies using OVID Medline and preprint servers (medRxiv, LitCovid, and SSRN) up until April 5, 2020; major journal sites were monitored for US publications until April 19, 2020. We pooled the prevalence of diarrhea, nausea, vomiting, and abdominal pain, as well as liver function tests abnormalities, using a fixed-effect model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework. RESULTS: We identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%-8.2%), nausea/vomiting 7.8% (95% CI, 7.1%-8.5%), and abdominal pain 2.7% (95% CI, 2.0%-3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%-16.5%) and alanine transaminase 15.0% (95% CI, 13.6%-16.4%). When we compared studies from China to studies from other countries in subgroup analyses, diarrhea, nausea/vomiting, and liver abnormalities were more prevalent outside of China, with diarrhea reported in 18.3% (95% CI, 16.6%-20.1%). Isolated GI symptoms were reported rarely. We also summarized the Gl and liver adverse effects of the most commonly utilized medications for COVID-19. CONCLUSIONS: GI symptoms are associated with COVID-19 in <10% of patients. In studies outside of China, estimates are higher. Further studies are needed with standardized GI symptoms questionnaires and liver function test checks on admission to better quantify and qualify the association of these symptoms with COVID-19. Based on findings from our meta-analysis, we provide several Best Practice Statements for the consultative management of COVID-19.

show abstract

Section: What Are the Gastrointestinal Manifestations Of Covid-19?mentioning

confidence: 99%

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…All studies were conducted between January 2020 and June 2020: 7 in January, 112 in February, 50 in March, 28 in April, 15 in May, and 3 in June. Seventeen preprint studies ( Chen et al, 2020a , 2020b ; Duan et al, 2020 ; Fu et al, 2020 ; Kuang et al, 2020 ; Li et al, 2020 ; Liu et al, 2020 ; Nie et al, 2020 ; Qi et al, 2020a , 2020b ; Qin et al, 2020 ; Shi et al, 2020 ; Song et al, 2020 ; Tao et al, 2020 ; Wen et al, 2020 ; Xu et al, 2020 ; Zhao et al, 2020 ) were included in the analysis. All the studies included in this meta-analysis were of retrospective design.…”

Section: Resultsmentioning

confidence: 99%

Clinical Features of COVID-19 Patients in the First Year of Pandemic: A Systematic Review and Meta-Analysis

Maqbali

Albadi

Sinani

et al. 2021

Biological Research For Nursing

View full text Add to dashboard Cite

Background The new coronavirus disease (COVID-19) carries a high risk of infection and has spread rapidly around the world. However, there are limited data about the clinical symptoms globally. The purpose of this systematic review and meta-analysis is to identify the prevalence of the clinical symptoms of patient with COVID-19. Methods A systematic review and meta-analysis were carried out. The following databases were searched: PubMed, CINAHL, MEDLINE, EMBASE, PsycINFO, medRxiv, and Google Scholar, from December 1st, 2019 to January 1st, 2021. Prevalence rates were pooled with meta-analysis using a random-effects model. Heterogeneity was tested using I-squared (I2) statistics. Results A total of 215 studies, involving 132,647 COVID-19 patients, met the inclusion criteria. The pooled prevalence of the four most common symptoms were fever 76.2% ( n = 214; 95% CI 73.9–78.5); coughing 60.4% ( n = 215; 95% CI 58.6–62.1); fatigue 33.6% ( n = 175; 95% CI 31.2–36.1); and dyspnea 26.2% ( n = 195; 95% CI 24.1–28.5). Other symptoms from highest to lowest in terms of prevalence include expectorant (22.2%), anorexia (21.6%), myalgias (17.5%), chills (15%), sore throat (14.1%), headache (11.7%), nausea or vomiting (8.7%), rhinorrhea (8.2%), and hemoptysis (3.3%). In subgroup analyses by continent, it was found that four symptoms have a slight prevalence variation—fever, coughing, fatigue, and diarrhea. Conclusion This meta-analysis found the most prevalent symptoms of COVID-19 patients were fever, coughing, fatigue, and dyspnea. This knowledge might be beneficial for the effective treatment and control of the COVID-19 outbreak. Additional studies are required to distinguish between symptoms during and after, in patients with COVID-19.

show abstract

Gastroenterological and Hepatic Manifestations of Patients with COVID-19, Prevalence, Mortality by Country, and Intensive Care Admission Rate: Systematic Review and Meta-analysis

Shehab

Alrashed

Shuaibi

et al. 2020

Preprint

View full text Add to dashboard Cite

Background & Aims Patient infected with the SARS-COV2 usually report fever and respiratory symptoms. However, multiple gastrointestinal (GI) manifestations such as diarrhea and abdominal pain has been described. The aim of this study was to evaluate the prevalence of GI, liver function test (LFT) abnormalities, and mortality of COVID19 patients. Methods We performed a systematic review and meta-analysis of published studies that included cohort of patients infected with SARSCOV2 from December 1st, 2019 to July 1st, 2020. We collected data from the cohort of patients with COVID19 by conducting a literature search using PubMed, Embase, Scopus, and Cochrane according to the preferred reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines. We analyzed pooled data on the prevalence of overall and individual gastrointestinal symptoms, LFTs abnormalities and performed subanalyses to investigate the relationship between gastrointestinal symptoms, geographic location, fatality, and ICU admission. Results The available data of 17,802 positive patients for SARS-COV2 from 120 studies were included in our analysis. The most frequent manifestations were diarrhea, nauseated elevated LFTs. The overall and GI fatality were 7.2% , and 1% respectively. Subgroup analysis showed non statistically significant associations between GI symptoms/LFTs abnormalities and ICU admissions (OR=3.41, 95%). The GI mortality rate was 0.58% in China and 3.5% in the United States. Conclusion Digestive symptoms and LFTs abnormalities are common in COVID-19 patients. Our subanalysis shows that the presence of gastrointestinal and liver manifestations does not appear to affect mortality, or ICU admission rate. However, the mortality rate was higher in the United States compared to China.

show abstract

Epidemiological and Clinical Characteristics of 944 Cases of 2019 Novel Coronavirus Infection of Non-COVID-19 Exporting City, Zhejiang, China

Cited by 6 publications

References 0 publications

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

Clinical Features of COVID-19 Patients in the First Year of Pandemic: A Systematic Review and Meta-Analysis

Gastroenterological and Hepatic Manifestations of Patients with COVID-19, Prevalence, Mortality by Country, and Intensive Care Admission Rate: Systematic Review and Meta-analysis

Contact Info

Product

Resources

About